Searched for
PATENT PROTECTION FOR KEYTRUDA
Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...- Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trialModerna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, redu...
- Biopharma Shakti: India targets China dependence, patent cliffIndia is launching a major initiative to boost its biopharmaceutical manufacturing. This plan aims to reduce reliance on China for crucial ...
- Merck to cut jobs and costs as demand for Gardasil in China remains weakMerck & Co revealed job and cost reductions to save $3 billion annually. This decision followed lower second-quarter results. Weak demand f...
- Go on, pop the innovation pill: ₹5,000 cr push signals India’s shift from copy to createIndia's pharma sector is poised for innovation-led growth, fueled by patent expirations and government support. The ₹5,000-cr PRIP scheme a...
- Pharma companies expected to absorb any tariff hit in short termU.S. tariffs on pharmaceuticals are unlikely to immediately raise brand-name drug prices, as drugmakers are expected to absorb initial cost...
- Big chase for a cancer drug: The urgent need for affordable Keytruda alternativesKeytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...
- How a drug major profited by slow-walking a promising HIV therapyToday, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment an...
- Merck wants to give products to Indians at affordable prices: Kenneth Frazier, Merck & CO"I see the progress made by the Modi administration towards not only ensuring that India can meet the needs of its people in healthcare, bu...
Load More
